|
1
|
Reck M, Rodríguez-Abreu D, Robinson AG,
Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe
S, et al: Pembrolizumab versus chemotherapy for PD-L1-positive
non-small-cell lung cancer. N Engl J Med. 375:1823–1833.
2016.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Rittmeyer A, Barlesi F, Waterkamp D, Park
K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols
MC, et al: Atezolizumab versus docetaxel in patients with
previously treated non-small-cell lung cancer (OAK): A phase 3,
open-label, multicentre randomised controlled trial. Lancet.
389:255–265. 2017.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Zhou Y, Chen C, Zhang X, Fu S, Xue C, Ma
Y, Fang W, Yang Y, Hou X, Huang Y, et al: Immune-checkpoint
inhibitor plus chemotherapy versus conventional chemotherapy for
first-line treatment in advanced non-small cell lung carcinoma: A
systematic review and meta-analysis. J Immunother Cancer. 6:1–11.
2018.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Herbst RS, Baas P, Kim DW, Felip E,
Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, et al:
Pembrolizumab versus docetaxel for previously treated,
PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010):
A randomised controlled trial. Lancet. 387:1540–1550.
2016.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Reck M, Rodríguez-Abreu D, Robinson AG,
Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe
S, et al: Updated analysis of KEYNOTE-024: Pembrolizumab versus
platinum-based chemotherapy for advanced non-small-cell lung cancer
with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol.
37:537–546. 2019.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Patel SP and Kurzrock R: PD-L1 expression
as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther.
14:847–856. 2015.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Hellmann MD, Ciuleanu TE, Pluzanski A, Lee
JS, Otterson GA, Audigier-Valette C, Minenza E, Linardou H, Burgers
S, Salman P, et al: Nivolumab plus ipilimumab in lung cancer with a
high tumor mutational burden. N Engl J Med. 378:2093–2104.
2018.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Gandara DR, Paul SM, Kowanetz M,
Schleifman E, Zou W, Li Y, Rittmeyer A, Fehrenbacher L, Otto G,
Malboeuf C, et al: Blood-based tumor mutational burden as a
predictor of clinical benefit in non-small-cell lung cancer
patients treated with atezolizumab. Nat Med. 24:1441–1448.
2018.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Ferrara R, Mezquita L, Texier M, Lahmar J,
Audigier-Valette C, Tessonnier L, Mazieres J, Zalcman G, Brosseau
S, Le Moulec S, et al: Hyperprogressive disease in patients with
advanced non-small cell lung cancer treated with PD-1/PD-L1
inhibitors or with single-agent chemotherapy. JAMA Oncol.
4:1543–1552. 2018.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Forschner A, Hilke FJ, Bonzheim I,
Gschwind A, Demidov G, Amaral T, Ossowski S, Riess O, Schroeder C,
Martus P, et al: MDM2, MDM4 and EGFR amplifications and
hyperprogression in metastatic acral and mucosal melanoma. Cancers
(Basel). 12(540)2020.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Shin DS, Zaretsky JM, Escuin-Ordinas H,
Garcia-Diaz A, Hu-Lieskovan S, Kalbasi A, Grasso CS, Hugo W,
Sandoval S, Torrejon DY, et al: Primary resistance to PD-1 blockade
mediated by JAK1/2 mutations. Cancer Discov. 7:188–201.
2017.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Kato S, Goodman A, Walavalkar V,
Barkauskas DA, Sharabi A and Kurzrock R: Hyperprogressors after
immunotherapy: Analysis of genomic alterations associated with
accelerated growth rate. Clin Cancer Res. 23:4242–4250.
2017.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Chen Y, Hu J, Bu F, Zhang H, Fei K and
Zhang P: Clinical characteristics of hyperprogressive disease in
NSCLC after treatment with immune checkpoint inhibitor: a
systematic review and meta-analysis. BMC Cancer.
20(707)2020.PubMed/NCBI View Article : Google Scholar
|
|
14
|
David CJ and Massagué J: Contextual
determinants of TGFβ action in development, immunity and cancer.
Nat Rev Mol Cell Biol. 19:419–435. 2018.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Shimmi O and Newfeld SJ: New insights into
extracellular and post-translational regulation of TGF-β family
signalling pathways. J Biochem. 154:11–19. 2013.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Li T, Wang H, Xu J, Li C, Zhang Y, Wang G,
Liu Y, Cai S, Fang W, Li J and Wang Z: TGFBR2 mutation predicts
resistance to immune checkpoint inhibitors in patients with
non-small cell lung cancer. Ther Adv Med Oncol.
13(17588359211038477)2021.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Rocco D, Della Gravara L, Battiloro C and
Gridelli C: The role of combination chemo-immunotherapy in advanced
non-small cell lung cancer. Expert Rev Anticancer Ther. 19:561–568.
2019.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Neel JC, Humbert L and Lebrun JJ: The dual
role of TGFβ in human cancer: From tumor suppression to cancer
metastasis. ISRN Mol Biol. 2012(381428)2012.PubMed/NCBI View Article : Google Scholar
|
|
19
|
MaruYama T, Chen W and Shibata H: TGF-β
and cancer immunotherapy. Biol Pharm Bull. 45:155–161.
2022.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Ettinger DS, Wood DE, Aisner DL, Akerley
W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, D'Amico
TA, et al: Non-small cell lung cancer, version 3.2022, NCCN
clinical practice guidelines in oncology. J Natl Compr Canc Netw.
20:497–530. 2022.PubMed/NCBI View Article : Google Scholar
|
